Erythema multiforme
☆ Ninu awọn abajade 2022 Stiftung Warentest lati Jẹmánì, itẹlọrun alabara pẹlu ModelDerm jẹ kekere diẹ ju pẹlu awọn ijumọsọrọ telemedicine isanwo.
Erythema multiforme minor - Ṣe akiyesi pe awọn ile-iṣẹ ti awọn ọgbẹ le ṣan.
Urticaria le tun jẹ ayẹwo bi ayẹwo iyatọ.
References
Erythema multiforme (EM) jẹ ipo nibiti awọn aaye ibi-afẹde pato ti han lori awọ ara ati awọn membran mucous nitori awọn aati ajẹsara. Botilẹjẹpe nigbagbogbo nfa nipasẹ awọn akoran ọlọjẹ, paapaa ọlọjẹ Herpes simplex (HSV) , tabi awọn oogun kan, idi naa ko jẹ aimọ ni ọpọlọpọ awọn ọran. Itoju EM nla fojusi lori irọrun awọn aami aisan nipa lilo awọn ipara ti o ni awọn sitẹriọdu tabi awọn antihistamines ninu. Ṣiṣakoso EM loorekoore jẹ imunadoko julọ nigbati a ṣe deede si alaisan kọọkan. Awọn isunmọ akọkọ jẹ pẹlu awọn itọju ẹnu ati ti agbegbe. Iwọnyi pẹlu awọn corticosteroids ati awọn oogun antiviral. Awọn itọju agbegbe ni awọn ipara sitẹriọdu ti o lagbara ati awọn ojutu fun awọn membran mucous ti o kan. Fun awọn alaisan ti ko dahun si awọn ajẹsara, awọn aṣayan ila-keji pẹlu awọn oogun ajẹsara, awọn oogun apakokoro, anthelmintics, ati awọn ibà.
Erythema multiforme (EM) is an immune-mediated condition that classically presents with discrete targetoid lesions and can involve both mucosal and cutaneous sites. While EM is typically preceded by viral infections, most notably herpes simplex virus (HSV), and certain medications, a large portion of cases are due to an unidentifiable cause. Treatment for acute EM is focused on relieving symptoms with topical steroids or antihistamines. Treatment for recurrent EM is most successful when tailored to individual patients. First line treatment for recurrent EM includes both systemic and topical therapies. Systemic therapies include corticosteroid therapy and antiviral prophylaxis. Topical therapies include high-potency corticosteroids, and antiseptic or anesthetic solutions for mucosal involvement. Second-line therapies for patients who do not respond to antiviral medications include immunosuppressive agents, antibiotics, anthelmintics, and antimalarials
Erythema multiforme (EM) is an immune-mediated condition that classically presents with discrete targetoid lesions and can involve both mucosal and cutaneous sites. While EM is typically preceded by viral infections, most notably herpes simplex virus (HSV), and certain medications, a large portion of cases are due to an unidentifiable cause. Treatment for acute EM is focused on relieving symptoms with topical steroids or antihistamines. Treatment for recurrent EM is most successful when tailored to individual patients. First line treatment for recurrent EM includes both systemic and topical therapies. Systemic therapies include corticosteroid therapy and antiviral prophylaxis. Topical therapies include high-potency corticosteroids, and antiseptic or anesthetic solutions for mucosal involvement. Second-line therapies for patients who do not respond to antiviral medications include immunosuppressive agents, antibiotics, anthelmintics, and antimalarials
Ni ọpọlọpọ awọn iṣẹlẹ, ìwọnba erythema multiforme lọ funrarẹ laarin ọsẹ meji si mẹrin. Aisan Stevens-Johnson, ipo ti o nira ti o kan awọn membran mucous, le ṣiṣe to ọsẹ mẹfa. Awọn sitẹriọdu ko ṣe iṣeduro ni igbagbogbo fun awọn ọran kekere. Boya awọn sitẹriọdu yẹ ki o lo fun erythema multiforme ti o lagbara ko ni idaniloju nitori ko si awọn awari ti o daju lati awọn iwadi ti a ti sọtọ ti o nfihan iru awọn ọmọde yoo ni anfani lati inu itọju yii.
In most cases, mild erythema multiforme is self-limited and resolves in 2 to 4 weeks. Stevens-Johnson syndrome is a serious disease that involves the mucous membranes and lasts up to 6 weeks. There is no indication for using steroids for the mild form. Use of steroids for erythema multiforme major is debatable because no randomized studies clearly indicate which children will benefit from this treatment.
In most cases, mild erythema multiforme is self-limited and resolves in 2 to 4 weeks. Stevens-Johnson syndrome is a serious disease that involves the mucous membranes and lasts up to 6 weeks. There is no indication for using steroids for the mild form. Use of steroids for erythema multiforme major is debatable because no randomized studies clearly indicate which children will benefit from this treatment.
A ṣafihan ọran ti oral erythema multiforme (EM) ti o ṣẹlẹ nipasẹ TMP/SMX , ti n ṣafihan aṣoju ẹnu ati ọgbẹ ẹnu laisi awọn ọgbẹ ara. Eyi tẹnumọ iwulo lati ṣe iyatọ rẹ si awọn rudurudu ọgbẹ ẹnu miiran. Alaisan naa gba itọju aami aisan ati awọn tabulẹti prednisolone, ti o yori si ilọsiwaju lẹhin idaduro TMP / SMX itọju ailera.
We report a case of oral erythema multiforme (EM) secondary to TMP/SMX that presented with oral and lip ulcerations typical of EM without any skin lesions and highlights the importance of distinguishing them from other ulcerative disorders involving oral cavity. The patient was treated symptomatically and given tablet prednisolone. The condition improved with stoppage of TMP/SMX therapy.
We report a case of oral erythema multiforme (EM) secondary to TMP/SMX that presented with oral and lip ulcerations typical of EM without any skin lesions and highlights the importance of distinguishing them from other ulcerative disorders involving oral cavity. The patient was treated symptomatically and given tablet prednisolone. The condition improved with stoppage of TMP/SMX therapy.
Erythema multiforme jẹ iṣesi ti o kan awọ ara ati nigbakan mucosa, ti o fa nipasẹ eto ajẹsara. Ni deede, o farahan bi awọn ọgbẹ ti o dabi ibi-afẹde, eyiti o le han sọtọ, ti nwaye, tabi tẹsiwaju. Awọn egbo wọnyi maa n ni ipa lori awọn iha opin, paapaa awọn aaye ita wọn. Awọn okunfa akọkọ pẹlu awọn akoran bii ọlọjẹ Herpes simplex ati Mycoplasma pneumoniae, ati awọn oogun kan, awọn ajẹsara, ati awọn arun autoimmune. Iyatọ erythema multiforme lati urticaria da lori iye akoko awọn ọgbẹ; Awọn egbo erythema multiforme wa titi fun o kere ju ọjọ meje, lakoko ti awọn egbo urticarial nigbagbogbo n parẹ laarin ọjọ kan. Botilẹjẹpe o jọra, o ṣe pataki lati ṣe iyatọ erythema multiforme lati aiṣan ti Stevens-Johnson ti o nira diẹ sii, eyiti o ṣafihan ni gbogbogbo erythematous tabi awọn macules purpuric pẹlu roro. Ṣiṣakoso erythema multiforme pẹlu iderun aami aisan pẹlu awọn sitẹriọdu ti agbegbe tabi awọn antihistamines ati sisọ idi ti o fa. Fun awọn iṣẹlẹ loorekoore ti o ni nkan ṣe pẹlu ọlọjẹ Herpes simplex, itọju ailera antiviral prophylactic jẹ iṣeduro. Ilowosi mucosal ti o lagbara le ṣe pataki ile-iwosan fun awọn omi inu iṣan ati rirọpo elekitiroti.
Erythema multiforme is a reaction involving the skin and sometimes the mucosa, triggered by the immune system. Typically, it manifests as target-like lesions, which may appear isolated, recur, or persist. These lesions usually symmetrically affect the extremities, particularly their outer surfaces. The main causes include infections like herpes simplex virus and Mycoplasma pneumoniae, as well as certain medications, immunizations, and autoimmune diseases. Distinguishing erythema multiforme from urticaria relies on the duration of lesions; erythema multiforme lesions remain fixed for at least seven days, while urticarial lesions often vanish within a day. Although similar, it's crucial to differentiate erythema multiforme from the more severe Stevens-Johnson syndrome, which typically presents widespread erythematous or purpuric macules with blisters. Managing erythema multiforme involves symptomatic relief with topical steroids or antihistamines and addressing the underlying cause. For recurrent cases associated with herpes simplex virus, prophylactic antiviral therapy is recommended. Severe mucosal involvement may necessitate hospitalization for intravenous fluids and electrolyte replacement.
Erythema multiforme is a reaction involving the skin and sometimes the mucosa, triggered by the immune system. Typically, it manifests as target-like lesions, which may appear isolated, recur, or persist. These lesions usually symmetrically affect the extremities, particularly their outer surfaces. The main causes include infections like herpes simplex virus and Mycoplasma pneumoniae, as well as certain medications, immunizations, and autoimmune diseases. Distinguishing erythema multiforme from urticaria relies on the duration of lesions; erythema multiforme lesions remain fixed for at least seven days, while urticarial lesions often vanish within a day. Although similar, it's crucial to differentiate erythema multiforme from the more severe Stevens-Johnson syndrome, which typically presents widespread erythematous or purpuric macules with blisters. Managing erythema multiforme involves symptomatic relief with topical steroids or antihistamines and addressing the underlying cause. For recurrent cases associated with herpes simplex virus, prophylactic antiviral therapy is recommended. Severe mucosal involvement may necessitate hospitalization for intravenous fluids and electrolyte replacement.
Ipo naa yatọ lati irẹwẹsi, sisu ti o ni opin ti ara ẹni si iwọn ti o buruju, eewu igbesi aye ti a mọ si erythema multiforme major ti o tun kan awọn membran mucous. Ikolu ti awọ ara mucous tabi niwaju awọn akọmalu jẹ awọn ami pataki ti idibajẹ.
- Erythema multiforme minor: aṣoju afojusun tabi dide, edematous papules pin acrally
Fọọmu ìwọnba naa maa n ṣafihan pẹlu irẹwẹsi ìwọnba (ṣugbọn nyún le jẹ lile pupọ), awọn abawọn pupa-pupa, ti a ṣeto ni isunmọ ati bẹrẹ lori awọn opin. Ipinnu ti sisu laarin awọn ọjọ 7-10 jẹ iwuwasi ni irisi arun na.
- Erythema multiforme major: awọn ibi-afẹde aṣoju tabi dide, awọn papules edematous pin kaakiri pẹlu ilowosi ti ọkan tabi diẹ sii awọn membran mucous. Iyọkuro Epidermal jẹ o kere ju 10% ti agbegbe agbegbe ti ara lapapọ.
○ Itọju - Oògùn OTC
Ti iba (iwọn otutu ti ara ga soke), o gba ọ niyanju lati ṣabẹwo si ile-iwosan ni kete bi o ti ṣee.
Awọn oogun ti a fura si yẹ ki o dawọ duro. (fun apẹẹrẹ awọn egboogi, awọn oogun egboogi-iredodo ti kii ṣe sitẹriọdu)
Awọn antihistamines ti ẹnu bi cetirizine ati loratadine fun nyún.
#Cetirizine [Zytec]
#LevoCetirizine [Xyzal]
#Loratadine [Claritin]